Venrock could book up to a 70x return from Eli Lilly's acquisition of cancer biotech Kelonia Therapeutics, partner Bryan Roberts tells Axios Pro.
Driving the news: Lilly said today it plans to pay $3.25 billion upfront for Kelonia in a deal that could total $7 billion if certain milestones are hit.
